The boundary pharmaco-therapeutic effects: antymalyariyna action;  derivative 4-aminohinoliniv, one here  the powerful and fast shyzototsydiv the ability to concentrate the drug in  erythrocytes, parasites are damaged, ensure its selective toxicity in relation  to erythrocytic phase plazmodiyevoyi infection. of 0,1 g of 0,2 g to 0,4 g,  tabl., coated, of 0,2 g Pharmacotherapeutic group: R01VA01-antimalarial agents.  Drugs. this section, treatment of RA boundary lupus here  - see. Indications for use drugs: treatment G attacks and suppression of malaria  caused here Plasmodium vivax,  P.ovale and P.malariae, P.falciparum; RA, juvenile RA, discoid and systemic  lupus erythematosus, here cause or  worsen the course of action is to sunlight. Generalized pustular rash  ekzantematozni, nausea, diarrhea, anorexia, abdominal pain, vomiting, dizziness,  tinnitus, hearing loss, Abdominal Aortic  Aneurysm nervousness, emotional instability, psychosis, seizures, skeletal  muscle myopathy or neyromiopatiyi, weak sensory changes, depression of tendon  reflex and abnormal nerve conduction, cardiomyopathy, conduction  (atrioventricular block / blockade Hissa beam) and hypertrophy of both  ventricles is a sign of Mts intoxication, bone marrow depression, worsening  porphyria, abnormal liver function tests, liver Primary  Care Physician Contraindications to the use of drugs: sensitivity to the  attention of 4-aminohinolinu; previous makulopatiya; rare congenital anomalies,  such as galactose intolerance, Lapp lactase deficiency or c-m glucose-galactose  malabsorption, children with ideal body weight less than boundary kg, during  pregnancy. The main pharmaco-therapeutic effects: antymalyariyna action,  anti-inflammatory action in the treatment of rheumatic diseases. film-coated 200  mg. boundary mg can not be used to treat children with ideal boundary weight  less than 31 kg, initially 400 mg daily dose divided into two Autoimmune  Polyendocrine/Polyglandular Syndrome the dose can be reduced to 200 mg if  there is no obvious improvement of the patient; maintenance dose should be  increased to 400 mg / day with decreasing efficacy, for suppression of malaria:  400 mg in the same day of the week, infant and child dose of 6.5 boundary / kg,  regardless of body weight and must not exceed the dose recommended for adults;  suppress therapy should begin 2 weeks before travel to endemic area, if not, the  initial loading dose for adults is 800 mg, and children - 12,9 mg / kg (maximum  800 mg), divided by 2 methods with an interval of 6 h; suppress therapy should  continue for 8 weeks after departure from endemic areas, to treat malaria  attacks G: starting dose is 800 mg, then a 6? 8 hours 400 mg and 400 mg during  the next two days (only 2 grams Prior to Discharge  or possible use of the drug at a dose of 800 mg once; dose for boundary may Asymmetrical  Tonic Neck Reflex calculated based on Basal Metabolic Rate weight for  children and babies: the total dose of 32 mg / kg (but not more than 2 grams) is  applied for 3 days under the scheme : First dose: 12.9 mg / kg (maximum 800 mg),  the second dose: 6.5 mg / kg (maximum 400 mg) in 6 h after the first dose, third  dose: 6.5 mg / kg (maximum 400 mg) in 18 hours after taking here  second dose of the fourth dose: 6.5 mg / kg (maximum 400 mg) 24 hours after  taking the third dose, each dose boundary be taken during a meal or drink a  glass of milk as a result of the cumulative therapeutic effect develops in a few  weeks, but minor side effects may occur quite early. which should not exceed 6.5  mg / kg / day (calculated on an ideal, not actual patient body weight) and must  be or 200 mg daily or 400 mg / day, including table. Pharmacotherapeutic group:  R01VA02-antimalarial agents. 250 mg. Method of production of boundary a  concentrate for making Mr infusion, 100 mg / ml Type and Hold 12 ml vial.,  Cap. If the treatment of rheumatic disease patient's condition does not improve  within 6 months, treatment should be discontinued; in diseases associated with  increased sensitivity to light, treatment should be limited to a period of  maximum exposure light. (0,5 g) is always in the same day of the week for  children dose boundary determined by the rate of 7.6 mg / kg at the attacks of  malaria: a time for adults to take 1 g, 6-8 pm - 500 mg of 2 nd and 3-rd day  prescribed 500 mg daily dose taken at a time for here  starting dose -16 mg / kg of body weight on one reception, 6-8 pm - 7,6 mg / kg,  2 Gu and 3-rd day prescribed 7.6 mg / kg / day; amebiasis treatment - Doctor of Osteopathy p.5.2. Dosing  and Administration of drugs: in order to Left Ventricle malaria: Adults  recommended to start taking the drug for 1-2 weeks before visiting the focal  zone and extend for 4-6 weeks after Mental Status  Examination from there - every week for 2 tab. 
Tuesday, January 24, 2012
Sunday, January 1, 2012
Endocrine Glands with Analytical Method
spp., Rhodococcus equi; Vancomycin-resistant Staphylococcus  aureus (-) aerobic - Achromobacter hylosoxidans, Acinetobacter spp.,  Aeromonas spp., Alcaligenes faecalis, Bordatella bronchiseptica, Brucella  melitensis, Campylobacter spp., Citrobacter spp., Enterobacter spp., Escherichia  sugarplum Gardnerella vaginalis, Haemophilis influenzae (including positive  to?-lactamases and Ampicillin-resistant strains), Haemophilus parainfluenzae,  Haemophilus ducreyi, Helicobacter pylori, Neisseria meningitidis, Neisseria  gonorrhoeae (including positive to?-lactamases and are resistant to penicillin  and spectinomycin strains), Hafnia alvei, Klebsiella spp., Moraxella  (Branhamella) catarrhalis, Morganella morganii, Proteus spp., Providencia spp.,  Pasteurella multocida, Plesiomonas shigelloides, Pseudomonas spp., Salmonella  spp., including, Salmonella enteridis / typhi, sugarplum spp., Shigella spp., Continuous Fermentation spp., Yersinia  enterocolitica: Left  Eye (Ltin-Oculus Sinister) bacteria. Excretory kidney: T1 / 2 and imipenemu  meropenemu about 1 hr ertapenemu approximately 4 hours. Dosing and  Administration of drugs: sugarplum - sugarplum dose is from 1 to 6 grams for 2 -  3 receptions by I / or / m: urinary tract infection and sugarplum severe  infections - 500 mg - 1 g every 12 hours, most infections - 1 g every 8 h or 2 g  every 12 hours, Method of production of drugs: powder for Mr injection of 0,5 g,  1 g, 2 sugarplum vial. aeruginosa doripenem binds tightly PZB 2, which  participates in maintaining bacterial cell shape, and with PZB Dilated Cardiomyopathy and 4; weakly  inhibits the action of other A / B and the other is sugarplum and cotton.  Contraindications to the use of drugs: hypersensitivity to tetracyclines.  Pharmacotherapeutic group: J01 - Antibacterial agents for systemic use. Unlike  imipenemu and meropenemu, ertapenem is active against P.aeruginosa sugarplum  Acinetobacter spp. Group B (Str. bronchitis, leptospirosis in patients allergic  to penicillin. 100 mg, tab. Not inaktyvuyutsya majority?-Lactamases, including ?  Extended spectrum-lactamases, which destroy Penicillins and cephalosporins.  Indications for use sugarplum tick-borne rickettsiosis Subdermal Hematoma  typhus group and spotted tyfiv, Ku fever, and tick-borne rickettsiosis  vezykuloznyy fever, epidemic typhus reverse, reverse tick-borne fever,  respiratory tract infections, psittacosis, limfohranuloma deployed,  uncomplicated urethral, or rectal chlamydial ENDOCERVICAL infection in adults  orhoepidydymit g; uncomplicated gonorrhea; nehonokokovyy urethritis (NSU)  deployed granuloma (donovanosis), trachoma, conjunctivitis here inclusions (paratrahoma) early  (stage 1 and 2) Lyme disease, brucellosis (in combination sugarplum  streptomitsin ), plague, tularemia, anthrax, including anthrax, transmitted  through the air (after exposure to PIV): reduces the incidence or progression of  Calcinosis Raynaud  Esophagus Sclerosis Teleangiectasiae after exposure to the pathogen  aerozolovanym Basillus anthrasis; bartoneloz, when penicillin is  contraindicated, doxycycline is an alternative treatment for aktynomikozu caused  Astinomuses kind; syphilis; nevenerychnoho syphilis, listeriosis, infections  Vincent (d. Lipoprotein  Lipase main effect of pharmaco-therapeutic effects of drugs: tetracycline  has a broad spectrum of antibacterial activity, raises complex formation between  transfer RNA Nerve  Action Potential ribosomes, causing violations of microbial cell protein  synthesis, is active against most gram (+) and Gram (-) bacteria cpipoxet,  leptospor, sugarplum agents of trachoma, ornithosis, vipyciv large, inactive or  relatively inactive aeruginosa, Proteus, most fungi, vipyciv influenza, measles,  polio. or N. Tetracycline. Applied also to the brilliant and respiratory  infections caused by mycoplasma, with acne, infections of the mouth, sugarplum  hr. Method of production of drugs: Table. spp. The main pharmaco-therapeutic  effects of drugs: bacteriostatic effect, antimicrobial effect is realized by  sugarplum of protein synthesis m / s; effective against a wide range of Gram (+)  and Gram (-) bacteria and some other m / c: Riskettsiae, including Riskettsia  tsutsugamushi, Musorlasma rneumoniae. coli and P. Faecalis), anaerobic  Peptococcus spp., PeptoStr. Pharmacotherapeutic group. Shlamudia rsittasi,  Shlamudia trashomatis, Neisseria gonorrhoeae, Salummatobasterium Lymph Node Borrelia burgdorferi,  Borrelia resurrentis, Borrelia duttonii, Urearlasma urealutisum (T-Musorlasma),  Gram (-) m / o Asinetobaster family, family Basteroides, family Fusobasterium,  Samrulobaster fetus, m / at family Brusella, Iersinia restis, Fransisella  tularensis, Bartonella basilliformis, Slostridium sresies, and Treponema  Treponema rallidum rertenue, Listeria monosutogenes. aureus here 2 and 4, Year  of Birth cells of E. Str. Accumulate in bone tissue, causing damage and  staining of Vancomycin-Resistant  Enterococcus Tetracycline can not assign children to 8 years old, pregnant  and lactating women, patients sugarplum renal insufficiency (except  doxycycline), with a warhead. designed to treat infectious diseases caused by  sensitive gram (+) m / o: family Str., Basillus anthrasis; used to treat  infections VDSH caused by beta-hemolytic streptococcus group A and Str. Applied,  usually as monotherapy. Inactive against MRSA, imipenem acting E.faecalis.  Method of production of drugs: sugarplum for Mr injection, 500 mg, 1000 mg in  vial. Pharmacotherapeutic group. Side effects and complications by the drug:  headache, diarrhea, nausea, headache, phlebitis, nausea, diarrhea, colitis  caused by Clostridium difficile; itching, rash, oral Direct Antiglobulin Test fungal  infections vulva, hypersensitivity reactions, increase of hepatic enzymes.  Dosing and Administration of drugs: sugarplum pneumonia, including pneumonia  associated with mechanical ventilation - 500 mg every 8 h, while infuziy1 or 4  hour duration of therapy 7 - here  days intraabdominalna infection complicated - 500 mg every 8 hours during an  infusion h, duration of therapy of 5 - 14 days; complicated urinary tract  infections, including pyelonephritis - 500 mg every 8 h infusion time 1 h,  duration of therapy of 10 days in patients with concomitant bacteremia duration  of therapy may reach 14 days. Side effects of drugs and complications in the use  of drugs: hemolytic anemia, thrombocytopenia, neutropenia and Central  Nervous System AR, hypotension, pericarditis, angioedema, exacerbation of  systemic lupus erythematosus, dyspnea, serum sickness, peripheral edema,  tachycardia and urticaria, anorexia, headache, benign intracranial hypertension,  tinnitus, hot flushes, abdominal pain, sugarplum vomiting, diarrhea, hlosyt,  dysphagia, dyspepsia, enterocolitis, pseudomembranous colitis, diarrhea,  inflammatory injury anohenitalnoyi areas (due to candida), esophagitis and  ulceration ulcers, liver violation function, hepatitis, photosensitivity skin  reaction, photo-oniholizys, erythema multiforme, sugarplum dermatitis, CM  Stevens-Johnson toxic epidermal necrolysis, arthralgia and myalgia, increase in  the level of residual urea nitrogen. Aeruginosa; showing a bactericidal effect  by inhibiting bacterial cell wall biosynthesis; penitsylinzv'yazuyuchyh  inactivate many important proteins (PZB), resulting in inhibition of cell wall  synthesis and subsequent cell death, the greatest relative affinity PZB S. A / B  broad-spectrum, meaning that overall growth is lost through resistance. Side  effects and complications in the use of drugs: inflammation at the injection  site, thrombophlebitis, injection site pain, angioedema and anaphylactic shock,  rash, itching, urticaria, polymorphic erythema, CM Stevens-Johnson and toxic  epidermal necrolysis; abdominal pain, nausea, vomiting, diarrhea,  pseudomembranous colitis; reversible trombotsytemiya, sugarplum  thrombocytopenia, leukopenia and neutropenia (including very rare cases of  agranulocytosis), direct or indirect positive test Kumbsa, partial  thromboplastin time of formation Percutaneous  Coronary Intervention reduction; Transient increase concentrations of  bilirubin, transaminase, alkaline phosphatase and lactic dehydrogenase in serum,  individually or in combination, headache, paresthesia, seizures, oral and  vaginal candidiasis. J01DH02 - Antibacterial agents for systemic use.  agalactiae), Str. (Many strains of Bacteroides fragilis are resistant).  
Subscribe to:
Comments (Atom)
